Read, Watch or Listen

U.S. health officials have issued a pause on the use of the chikungunya vaccine, Ixchiq, following reports of serious adverse events, including neurological and cardiac issues. The FDA and CDC are investigating these post-marketing reports, particularly focusing on individuals over 60. While 17 serious adverse events were reported globally, officials emphasize that a causal link to the vaccine isn't yet established. Ixchiq was approved in November 2023 for adults at increased risk of chikungunya, a mosquito-borne virus causing fever, rash, and joint pain. The pause comes amidst broader scrutiny of vaccine use.

Prepared by Olivia Bennett and reviewed by editorial team.